HER2+ BC: Residual Disease After Neoadjuvant Therapy - Episode 3
Sara M. Tolaney, MD, MPH:T-DM1 is an antibody drug conjugate that consists of trastuzumab linked to emtansine. Emtansine is a very potent antimicrotubule agent. When this antibody drug conjugate binds to HER2,it gets taken in intracellularly, and then the linker releases the emtansine intracellularly, resulting in cell death. So it’s a very clever mechanism to deliver very potent chemotherapy into the cancer cell. I think some people like to think of these antibody drug conjugates as smart bombs because of their very targeted delivery of chemotherapy.
Given data from KATHERINE, I do think that any patient who has residual disease after trastuzumab-based chemotherapy should be offered 14 cycles of TDM-1 because, again, it was associated with a 50% reduction in invasive disease-free survival events. I do think it also makes us realize the importance of giving therapy in the preoperative setting, because it allows us to better understand response to therapy and then tailor adjuvant treatment based on this response. Prior to KATHERINE people weren’t uniformly giving patients with locally advanced HER2-positive disease preoperative treatment. We knew data that suggested that preoperative therapy yielded similar outcomes to adjuvant therapy, and so we didn’t feel like we had to give the therapy in the preoperative setting. But now seeing that we can tailor treatment based on response to preoperative therapy, I think it should push us to utilize treatment preoperatively, particularly for those patients who have tumors larger than 2 cm, or who have clinically lymph node-positive disease.
Transcript edited for clarity.
Case: A 49-Year-Old Woman With HER2+ Breast Cancer
H & P
Biopsy and labs: